BETAXOLOL HYDROCHLORIDE (be-tax'oh-lol) Betoptic, Betoptic-S, Kerlone Classifications: eye preparation; miotic (antiglaucoma agent); beta-adrenergic blocker; antihypertensive agent; Therapeutic: antiglaucoma agent (miotic); antihypertensive agent Prototype: Propranolol Pregnancy Category: C |
10 mg, 20 mg tablets; 0.25%, 0.5% ophthalmic solution
Acts as a beta1-selective adrenergic receptor blocking agent, especially in the cardioselective beta1 receptors. Its antihypertensive effect is thought to be due to: (1) decreasing cardiac output, (2) reducing sympathetic nervous system outflow to the periphery resulting in vasodilatation, and (3) suppression of renin activity in the kidney. It reduces intraocular pressure within the eye by decreasing the production of aqueous humor.
All three mechanisms result in its antihypertensive effect.
Hypertension. Ocular use for intraocular hypertension, chronic open angle glaucoma (see Appendix A-1).
Sinus bradycardia, AV block greater than first degree, cardiogenic shock, severe left ventricular heart failure; glaucoma, angle closure (unless with a miotic); pregnancy (category C); children <18 y.
Concomitant use of systemic beta-adrenergic blocking agents; history of heart failure; renal impairment, elderly; hyperthyroidism or thyrotoxicosis; diabetes mellitus; with evidence of airflow obstruction or reactive airway disease; depression; lactation.
Hypertension Adult: PO 510 mg q.d. (max: 20 mg/d in 12 divided doses) Renal Impairment Clcr <10mL/min: administer 50% of dose |
Assessment & Drug Effects
Patient & Family Education